Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Free Cash Flow: 2009-2024

Historic Free Cash Flow for Cytokinetics (CYTK) over the last 16 years, with Dec 2024 value amounting to -$399.8 million.

  • Cytokinetics' Free Cash Flow fell 14.34% to -$116.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$453.4 million, marking a year-over-year decrease of 11.39%. This contributed to the annual value of -$399.8 million for FY2024, which is 3.83% up from last year.
  • According to the latest figures from FY2024, Cytokinetics' Free Cash Flow is -$399.8 million, which was up 3.83% from -$415.7 million recorded in FY2023.
  • In the past 5 years, Cytokinetics' Free Cash Flow ranged from a high of -$2.1 million in FY2020 and a low of -$415.7 million during FY2023.
  • For the 3-year period, Cytokinetics' Free Cash Flow averaged around -$375.5 million, with its median value being -$399.8 million (2024).
  • As far as peak fluctuations go, Cytokinetics' Free Cash Flow skyrocketed by 97.75% in 2020, and later tumbled by 8,975.11% in 2021.
  • Cytokinetics' Free Cash Flow (Yearly) stood at -$2.1 million in 2020, then plummeted by 8,975.11% to -$191.4 million in 2021, then crashed by 62.41% to -$310.9 million in 2022, then crashed by 33.75% to -$415.7 million in 2023, then climbed by 3.83% to -$399.8 million in 2024.